{
  "id": 7042138,
  "title": "Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer",
  "url": "https://urgent.news/2026/09/13/ivonescimab-significantly-improves-overall-survival-versus",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T01:50:08.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-ivonescimab-significantly-survival-pembrolizumab-advanced.html"
  },
  "original_language": "en",
  "account": "A new analysis of the phase 3 HARMONi-2 trial has found that the first-in-class PD-1/VEGF bispecific antibody ivonescimab significantly extends overall survival compared to the PD-1 inhibitor pembrolizumab in patients with treatment-naive advanced non-small cell lung cancer (NSCLC) that is PD-L1 positive. The trial enrolled 398 patients at centers in China between November 2022 and August 2023. Patients were randomly assigned to receive ivonescimab or pembrolizumab and followed for a median of 30.8 months with ivonescimab versus 22.6 months with pembrolizumab (HR 0.73; 95% CI 0.57--0.95; P=0.009). The survival benefit was consistent across subgroups of patients with squamous or nonsquamous histology and different levels of PD-L1 expression. While ivonescimab was associated with more treatment-related adverse events, the safety profile was comparable to pembrolizumab in terms of serious adverse events, discontinuations, and immune-related events.",
  "summary": "Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}